Breast Cancer Research and Treatment **52**: 333, 1998.
© 1998 *Kluwer Academic Publishers. Printed in the Netherlands.*

Author index, Volume 52

Allred DC 79
Altman DG 289

Barnes DM 1
Bianco AR 55
Braun S 201
Brown PD 125
Brünner N 99

Cariou S 29
Carlomagno C 55
Catzavelos C 29
Chamness GC 227
Clark GM 227
Colnaghi MI 137

Dahiya R 185
de Moor C 227
De Laurentiis M 55
De Placido S 55
Deng G 185

Elledge RM 79
Ellis MJ 175

Fanelli M 159
Ferguson D 147

Gasparini G 159,321
Gillett CE 1
Gray S 147
Gullick WJ 43

Hanfelt J 175
Harris AL 175,305
Hayes DF 239,305
Heimann R 147
Hellman S 147
Henderson IC 261
Hilsenbeck SG 227

Ishigaki S 113

Jänicke F 99
Jatoi I 217
Jenkins S 175

Leek R 175
Locopo N 159
Lyman GH 289

Ménard S 137

Osborne CK 227

Pantel K 201
Patek AJ 261
Pauletti G 65
Pegram MD 65

Ravdin PM 227
Redington ME 175

Schmitt M 99
Siddle K 175
Slamon DJ 65
Slingerland JM 29
Srinivasan R 43
Stearns V 239
Steeg PS 17
Stephens RW 99

Tagliabue E 137
Taylor M 175
Toi M 113
Tominaga T 113
Trock B 305

Yamauchi H 239

Zhou Q 17

Breast Cancer Research and Treatment **52**: 335-337, 1998.
© 1998 *Kluwer Academic Publishers. Printed in the Netherlands.*

Subject index, Volume 52

adhesion
role of the 67 kDa laminin receptor, and prognosis 137-145
angiogenesis
association with matrix metalloproteinases 113-124
microvessel count in prognosis — methodologic issues 147-158
apoptosis
stress response altered by IGF1R signalling 175-184

bone marrow
methods for detection of micrometastases, and prognosis 201-216
BRCA-1 and -2
as molecular markers of prognosis 185-200

chemotherapy
erbB-2 in predicting treatment response 65-77
IGF system components as predictive factors for response 175-184
chromosomal aberrations
as molecular markers of prognosis 185-200
collagenases
see matrix metalloproteinases
cyclin D
roles in breast cancer 17-28
transactivation of estrogen receptor 17-28
cyclin D1
overexpression and improved prognosis 1-15
cyclin E
G1 cyclins in breast cancer 17-28
cyclin-dependent kinase inhibitor p27
overexpression and improved outcome 1-15
prognostic significance of loss 29-41
cytokeratins
as markers for detecting micrometastases in bone marrow 201-216

ductal carcinoma in situ (DCIS)
overexpression of cyclins D and E 17-28

EGF receptor
receptor family members in prognosis and treatment response 43-53
endocrine therapy
erbB-2 as a predictive factor for tamoxifen resistance 55-64,65-77
IGF system components as predictive factors for response 175-184
positive predictive effect of cyclin D1 overexpression 1-15
erbB oncogenes
as molecular markers of prognosis 185-200
erbB-2
and tamoxifen efficacy 55-64
as a predictive marker of treatment response 65-77
circulating, clinical utilities 239-259
receptor family members in prognosis and treatment response 43-53
relationship between prognostic and predictive factors 261-288
estrogen
unopposed — hypothesis for effect of menstrual timing of surgery on prognosis 217-225
estrogen receptor
phosphorylation induced by IGF1R activation 175-184
positive association with cyclin D1, p27 1-15
relationship between prognostic and predictive factors 261-288
transactivation by cyclin D 17-28
extracellular matrix
the uPA system in prognosis 99-111

gelatinases
see matrix metalloproteinases

HER 1–4
new family ligands and receptors — role in breast cancer 43-53
HER-2/*neu*
see erbB-2

Herceptin®
in treatment of erbB-2 overexpressing breast cancer 65-77
heregulin
erbB receptor family members in prognosis and treatment response 43-53
heterodimerization
of erbB receptor family members in prognosis and treatment response 43-53
hormone therapy
see endocrine therapy

insulin-like growth factor (IGF) system
and sensitivity to radiation, chemotherapy, and endocrine therapy 175-184
integrins
α_6 and $\alpha_v\beta_3$ — endothelial adhesion molecules in prognosis 159-173
67 kDa laminin receptor as an accessory adhesion molecule 137-145
invasion
matrix metalloproteinases and TIMPs in prognosis 113-124
the uPA system in prognosis 99-111

laminin receptor
67 kDa, in cell adhesion and prognosis 137-145
loss of heterozygosity (LOH)
as a molecular marker of prognosis 185-200

matrix metalloproteinases
drug design of inhibitors as chemotherapeutics 125-136
MMPs and TIMPs in prognosis 113-124
menstrual cycle
timing of surgery, and prognosis 217-225
meta-analysis
methodologic considerations for prognostic studies 289-303
metastasis
prevention by designed MMP-inhibiting drugs 125-136
the uPA system in prognosis 99-111
metastatic disease
monitoring by circulation tumor markers 239-259
micrometastases
methods for detection in bone marrow, and prognosis 201-216
microsatellite instability
as a molecular marker of prognosis 185-200
microvessel count
see angiogenesis
mucins
as markers for detecting micrometastases in bone marrow 201-216
multidrug resistance (MDR) gene
as a molecular marker of prognosis 185-200

neovascularization
see angiogenesis

$p21^{WAF-1}$
lack of promise as a prognostic factor 79-98
p27
see cyclin-dependent kinase inhibitor p27
p53
as a molecular marker of prognosis 185-200
as a prognostic and predictive factor 79-98
PAI-1 and 2
the uPA system in prognosis 99-111
paracrine interactions
MMPs in tumor-stromal interactions 113-124
patient management
assessing the clinical impact of prognostic and predictive factors 305-319
clinical utilization of prognostic and predictive factors 261-288
platelet-derived endothelial cell growth factor
angiogenic factors in prognosis and response prediction 159-173
predictive factors
assessing the clinical impact 305-319
circulating tumor markers 239-259
clinical utilization and relationship with prognostic factors 261-288
cyclin D1 overexpression and endocrine therapy 1-15
editorial summary 321-331
EGFR and erbB receptor family members 43-53
erbB-2 and tamoxifen efficacy 55-64
erbB-2 in response to chemo and endocrine therapy 65-77

predictive factors *[continued]*
extracellular domain of HER-2/*neu* in serum 239-259
IGF system components and sensitivity to radiation, chemotherapy, and endocrine therapy 175-184
possible role of p53 79-98
possible value of angiogenic factors (e.g. VEGF) 159-173
progesterone
and unopposed estrogen — hypothesis for effect of menstrual timing of surgery on prognosis 217-225
prognostic factors
angiogenesis, by microvessel count — methodologic issues 147-158
angiogenic factors and endogenous angiogenesis inhibitors 159-173
assessing the clinical impact 305-319
circulating tumor markers 239-259
clinical utilization and relationship with predictive factors 261-288
cyclin D1 overexpression and improved outcome 1-15
cyclin-dependent kinase inhibitor p27 and improved outcome 1-15
editorial summary 321-331
EGFR and erbB receptor family members 43-53
extracellular domain of HER-2/*neu* in serum 239-259
laminin receptor, 67 kDa 137-145
loss of cdk inhibitor p27 and poor outcome 29-41
matrix metalloproteinases and TIMPs 113-124
micrometastases in bone marrow, and detection methods 201-216
molecular markers (BRCAs, p53, erbBs, LOH, TGFα, MDR) 185-200
p53 and $p21^{WAF-1}$ 79-98
statistical/methodologic issues 99-111
study design and analysis 289-303
time dependence of hazard ratios 227-237
uPA system components 99-111

radiation therapy
IGF system components as predictive factors for response 175-184

serum markers
for prognosis, response prediction, and monitoring disease response 239-259
statistical methods
in prognostic studies of the uPA system 99-111
methodologic considerations for prognostic studies 289-303
time dependence of hazard ratios for prognostic factors 227-237
stromelysins
see matrix metalloproteinases
study design
methodologic considerations for prognostic studies 289-303
surgery
timing during the menstrual cycle, and prognosis 217-225

tamoxifen
erbB-2 as a predictive factor for resistance 55-64,65-77
thrombospondins
as angiogenesis inhibitors, in prognosis 159-173
TIMPs (tissue inhibitors of metalloproteinases)
and drug design of MMP inhibitors as chemotherapeutics 125-136
and MMPs in prognosis 113-124
transforming growth factor alpha (TGFα)
as a molecular marker of prognosis 185-200
treatment decisions
see patient management
treatment response
see predictive factors
Tumor Marker Utility Grading System (TMUGS)
extension for assessing clinical impact of prognostic and predictive factors 305-319
in evaluation of circulating tumor markers for clinical applications 239-259

uPA (urokinase plasminogen activator) system
uPA and PAI-1 and 2 in prognosis 99-111

vascular endothelial growth factor (VEGF)
angiogenic factors in prognosis and response prediction 159-173